Drugs / MOD-5014
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02919800 | Jan 2017 → Feb 2018 | inherited blood coagulation disorder | OPKO Health, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02418793 | May 2015 → Sep 2018 | hemophilia A, hemophilia B | OPKO Health, Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MOD-5014 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02919800 ↗ |
| Modality | Protein / enzyme biologic | “Long Acting Recombinant FVIIa” NCT02418793 ↗ |
| Route | Subcutaneous | “single SC injection of MOD-5014” NCT02919800 ↗ |